滨蒿内酯对实验性变应性鼻炎大鼠维甲酸相关孤儿核受体γt及相关因子表达的影响
|
摘要
目的探讨滨蒿内酯(scoparone,Sco)对实验性变应性鼻炎大鼠的行为、病理,血清中IL-17、IL-23及鼻黏膜组织中维甲酸相关孤儿核受体(retinoic acidrelated orphan receptor gamma t,RORγt)、白细胞介素17(IL-17)、IL-23 mRNA含量的影响。方法构建动物模型,分为正常对照组(NC组)、变应性鼻炎组(AR组)、滨蒿内酯组(Sco组)和地塞米松组(Dxm组),对大鼠症状进行评分,HE染色鼻黏膜,ELISA法检测血清中IL-17、IL-23含量,RT-PCR检测鼻黏膜组织中RORγt、IL-17及IL-23 mRNA表达。结果实验组经滨蒿内酯治疗后症状及炎症病理缓解。Sco组和Dxm组血清IL-17、IL-23较NC组稍高。AR组大鼠RORγt、IL-17及IL-23 mRNA含量均显著高于其他三组。Sco组和Dxm组RORγt、IL-17及IL-23 mRNA较NC组稍高。结论 Sco对大鼠变应性鼻炎的过敏症状具有明显的抑制或消除作用,能降低疾病的严重程度和炎症反应。
OBJECTIVE To invest igate the effects of behavior, pathology, the serum IL-17, IL-23 level, and the expressing of RORγt, IL-17 and IL-23 mRNA in nasal tissues of experimental allergic rhinitis rats after the scoparone treatment. METHODS The animal model were divided into 4 groups: normal control group(group NC), allergic rhinitis group(group AR), artemolactone group(group Sco) and dexamethasone group(group Dxm). The symptom score, HE staining of the nasal mucosa, IL-17 and IL-23 level in serum measured by ELISA, the RORγt, IL-17 and IL-23 mRNA level detected by RTPCR. RESULTS Symptoms and inflammatory pathology were relieved in the experimental group after scoparone treatment. The serum levels of the IL-17, IL-23 in group Sco and group Dxm were little higher than that in group NC. The levels of RORγt, IL-17 and IL-23 mRNA in group AR were significantly higher than that in the other three groups. The levels of RORγt, IL-17 and IL-23 mRNA in group Sco and group Dxm were little higher than that in the group NC. CONCLUSION Sco could significantly inhibited or eliminated the allergy symptoms of AR in rats, and could reduce the severity and inflammatory response of diseases.
OBJECTIVE To invest igate the effects of behavior, pathology, the serum IL-17, IL-23 level, and the expressing of RORγt, IL-17 and IL-23 mRNA in nasal tissues of experimental allergic rhinitis rats after the scoparone treatment. METHODS The animal model were divided into 4 groups: normal control group(group NC), allergic rhinitis group(group AR), artemolactone group(group Sco) and dexamethasone group(group Dxm). The symptom score, HE staining of the nasal mucosa, IL-17 and IL-23 level in serum measured by ELISA, the RORγt, IL-17 and IL-23 mRNA level detected by RTPCR. RESULTS Symptoms and inflammatory pathology were relieved in the experimental group after scoparone treatment. The serum levels of the IL-17, IL-23 in group Sco and group Dxm were little higher than that in group NC. The levels of RORγt, IL-17 and IL-23 mRNA in group AR were significantly higher than that in the other three groups. The levels of RORγt, IL-17 and IL-23 mRNA in group Sco and group Dxm were little higher than that in the group NC. CONCLUSION Sco could significantly inhibited or eliminated the allergy symptoms of AR in rats, and could reduce the severity and inflammatory response of diseases.
引文
[1]Nelson HS.Allergen immunotherapy now and in the future.Allergy Asthma Proc,2016,37(4):268-272.
[2]成丽兰,王珍,姜翠菊,等.滨蒿内酯对大鼠血清Th1/Th2细胞因子及IgE表达的影响.临床耳鼻咽喉头颈外科杂志,2013,27(23):1310-1312.
[3]赵鹤,曹志伟,顾兆伟,等.IL-9在变应性鼻炎小鼠模型鼻黏膜中的表达研究.中国耳鼻咽喉颅底外科杂志,2015,21(1):4-7.
[4]熊瑛,章诗富,成丽兰,等.滨蒿内酯治疗变应性鼻炎的实验研究.贵阳医学院学报,2011,36(5):452-454,459.
[5]Zhang Y,Zhang L.Prevalence of allergic rhinitis in china.Allergy Asthma Immunol Res,2014,6(2):105-113.
[6]Bousquet J,Khaltaev N,Cruz AA,et al.Allergic Rhinitis and its Impact on Asthma(ARIA)2008 update(in collaboration with the WorldHealth Organization,GA(2)LEN and AllerGen).Allergy,2008,63 Suppl 86:8-160.
[7]中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎诊断和治疗指南(2015年,天津).中华耳鼻咽喉头颈外科杂志,2016,51(1):6-24.
[8]Kolls JK,Lindén A.Interleukin-17 family members and inflammation.Immunity,2004,21(4):467-476.
[9]Qu N,Xu M,Mizoguchi I,et al.Pivotal roles of T-helper17-related cytokines,IL-17,IL-22,and IL-23,in inflammatory diseases.Clin Dev Immunol,2013,2013:968549.
[10]Bettelli E,Carrier Y,Gao W,et al.Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.Nature,2006,441(7090):235-238.
[11]Lajoie S,Lewkowich IP,Suzuki Y,et al.Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma.Nat Immunol,2010,11(10):928-935.
[12]Manel N,Unutmaz D,Littman DR.The differentiation of human T(H)-17 cells requires transforming growth factor-beta and inductionof the nuclear receptor RORgammat.Nat Immunol,2008,9(6):641-649.
[13]LaPan P,Zhang J,Pan J,et al.Quantitative optimization of reverse transfection conditions for 384-well siRNA library screening.Assay Drug Dev Techno,2008,6(5):683-691.
[14]Rauen T,Juang YT,Hedrich CM,et al.A novel isoform of the orphan receptor RORγt suppresses IL-17 production in human Tcells.Genes Immun,2012,13(4):346-350.
[15]王勇.针刺调节Notch信号介导气道高反应Foxp3/RoRγt失衡的机制研究.广州:广州中医药大学,2015.
[16]李绍波,陈玲玲,赖小英,等.哮喘大鼠肺组织T-bet、GATA-3和RORγt mRNA表达变化及特异性免疫治疗的干预影响.现代实用医学,2017,29(7):879-881.
[17]Solt LA,Burris TP.Action of RORs and their ligands in(patho)physiology.Trends Endocrinol Metab,2012,23(12):619-627.
[18]Harrington LE,Hatton RD,Mangan PR,et al.Interleukin17-producing CD4+effector T cells develop via a lineage distinct from the T helpertype 1 and 2 lineages.Nat Immunol,2005,6(11):1123-1132.
[19]Rauen T,Juang YT,Hedrich CM,et al.A novel isoform of the orphan receptor RORγt suppresses IL-17 production in human Tcells.Genes Immun,2012,13(4):346-350.
[20]Wang S,Tang Q,Qian W,et al.Meta-analysis of clinical trials on traditional Chinese herbal medicine for treatment of persistentallergic rhinitis.Allergy,2012,67(5):583-592.
[21]杨燕,王庆伟,张琰.滨蒿内酯的研究进展.中国药业,2011,20(19):1-3.
[2]成丽兰,王珍,姜翠菊,等.滨蒿内酯对大鼠血清Th1/Th2细胞因子及IgE表达的影响.临床耳鼻咽喉头颈外科杂志,2013,27(23):1310-1312.
[3]赵鹤,曹志伟,顾兆伟,等.IL-9在变应性鼻炎小鼠模型鼻黏膜中的表达研究.中国耳鼻咽喉颅底外科杂志,2015,21(1):4-7.
[4]熊瑛,章诗富,成丽兰,等.滨蒿内酯治疗变应性鼻炎的实验研究.贵阳医学院学报,2011,36(5):452-454,459.
[5]Zhang Y,Zhang L.Prevalence of allergic rhinitis in china.Allergy Asthma Immunol Res,2014,6(2):105-113.
[6]Bousquet J,Khaltaev N,Cruz AA,et al.Allergic Rhinitis and its Impact on Asthma(ARIA)2008 update(in collaboration with the WorldHealth Organization,GA(2)LEN and AllerGen).Allergy,2008,63 Suppl 86:8-160.
[7]中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎诊断和治疗指南(2015年,天津).中华耳鼻咽喉头颈外科杂志,2016,51(1):6-24.
[8]Kolls JK,Lindén A.Interleukin-17 family members and inflammation.Immunity,2004,21(4):467-476.
[9]Qu N,Xu M,Mizoguchi I,et al.Pivotal roles of T-helper17-related cytokines,IL-17,IL-22,and IL-23,in inflammatory diseases.Clin Dev Immunol,2013,2013:968549.
[10]Bettelli E,Carrier Y,Gao W,et al.Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.Nature,2006,441(7090):235-238.
[11]Lajoie S,Lewkowich IP,Suzuki Y,et al.Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma.Nat Immunol,2010,11(10):928-935.
[12]Manel N,Unutmaz D,Littman DR.The differentiation of human T(H)-17 cells requires transforming growth factor-beta and inductionof the nuclear receptor RORgammat.Nat Immunol,2008,9(6):641-649.
[13]LaPan P,Zhang J,Pan J,et al.Quantitative optimization of reverse transfection conditions for 384-well siRNA library screening.Assay Drug Dev Techno,2008,6(5):683-691.
[14]Rauen T,Juang YT,Hedrich CM,et al.A novel isoform of the orphan receptor RORγt suppresses IL-17 production in human Tcells.Genes Immun,2012,13(4):346-350.
[15]王勇.针刺调节Notch信号介导气道高反应Foxp3/RoRγt失衡的机制研究.广州:广州中医药大学,2015.
[16]李绍波,陈玲玲,赖小英,等.哮喘大鼠肺组织T-bet、GATA-3和RORγt mRNA表达变化及特异性免疫治疗的干预影响.现代实用医学,2017,29(7):879-881.
[17]Solt LA,Burris TP.Action of RORs and their ligands in(patho)physiology.Trends Endocrinol Metab,2012,23(12):619-627.
[18]Harrington LE,Hatton RD,Mangan PR,et al.Interleukin17-producing CD4+effector T cells develop via a lineage distinct from the T helpertype 1 and 2 lineages.Nat Immunol,2005,6(11):1123-1132.
[19]Rauen T,Juang YT,Hedrich CM,et al.A novel isoform of the orphan receptor RORγt suppresses IL-17 production in human Tcells.Genes Immun,2012,13(4):346-350.
[20]Wang S,Tang Q,Qian W,et al.Meta-analysis of clinical trials on traditional Chinese herbal medicine for treatment of persistentallergic rhinitis.Allergy,2012,67(5):583-592.
[21]杨燕,王庆伟,张琰.滨蒿内酯的研究进展.中国药业,2011,20(19):1-3.